DESMOPLASTIC MELANOMA REVIEW

Clinical and Dermoscopic Characteristics of Desmoplastic Melanomas

Objective: To describe and analyze the clinical and dermoscopic characteristics of desmoplastic melanoma (DM) as a function of pathologic subtype and phenotypic traits.

Image result for DESMOPLASTIC MELANOMA REVIEW

Design: Retrospective case series.

Setting: Eight high-risk dermatology clinics.

Patients: Patients with DM confirmed by histopathologic analysis whose records included a high-quality dermoscopic image.

Main Outcome Measures: Clinical, dermoscopic, and histopathologic features of DM.

Results: A total of 37DMcases were identified. The majority of patients had fair skin, few nevi, and no history of melanoma. Lentigo maligna was the most frequent subtype of melanoma associated with DM. The most frequent clinical presentation of DM was a palpable and/or indurated lesion located on the sun-exposed skin. Forty-three percent of cases were classified as pure DM, and 57% as mixed DM. Pure DM lesions were thicker than mixed DM lesions (4.10 vs 2.83 mm) (P=.22) and were less likely to have an associated epidermal non-DM component (63% vs 100%) (P=.004). Dermoscopically, DMs had at least 1 melanoma-specific structure, the most frequent being atypical vascular structures. Peppering was more frequently seen in pure DM (44% in pure DM vs 24% in mixed DM) (P=.29). In contrast, crystalline structures, polymorphous vessels, and vascular blush were more commonly seen in mixed DM.

Conclusions: Though DM can be difficult to diagnose based on clinical morphologic characteristics alone, dermoscopy has proved to be a useful aid during the evaluation of clinically equivocal lesions or those lesions with a benign appearance. The most common dermoscopic clues observed in DMs included atypical vascular structures, peppering, and occasionally other melanoma-specific structures.

Comments

HYFRECATORS AND INTERFERENCE WITH IMPLANTABLE CARDIAC DEVICES

Investigation of Hyfrecators and They are In Vitro Interference with Implantable Cardiac Devices CHRISTOPHER WEYER, DO,* RONALD J. SIEGLE, MD,†‡ AND GUILLAUME GIRARD P. ENG, EMI-EMC§ BACKGROUND Guidelines exist for minimizing potential electromagnetic interference (EMI) with electrosurgical equipment in patients with cardiac rhythm management (CRM) devices. These guidelines encompass all electrosurgical devices but are not speciﬁc for hyfrecators. OBJECTIVE To investigate the potential interference of CRM devices by hyfrecators. MATERIALS AND METHODS Using a collagen-based saline gel, three implantable pulse generators (pacemakers) and three implantable cardioverter deﬁbrillators were tested to measure the EMI from two commonly used hyfrecators. The six devices were tested using the hyfrecator under normal use settings and on maximum power. RESULTS Hyfrecators did not interfere with deﬁbrillators and affected pacemakers only when used in close proximity to the devi...

NEW DRUG THERAPY FOR BCC

Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. BCC is the most common type of skin cancer, which is generally considered curable by surgery. However, when it advances, BCC can cause disfiguring and debilitating effects and can ultimately be life-threatening. “We are excited by the pivotal study results that showed vismodegib substantially reduced tumor size or healed lesions for people with this rare skin cancer, which has no approved ...

TRANSACTION AND MELANOMA SURVIVAL

The rate of melanoma transaction with various biopsy techniques and the influence of tumor transaction on patient survival Mohsin Mir, MD, C. Stanley Chan, MD, Farhan Khan, MD, MBA, Bhuvaneswari Krishnan, MD, Ida Orengo, MD, and Theodore Rosen, MD Houston, Texas Background: Depth of melanoma invasion is critical because it dictates patient treatment and prognosis. Recent reports indicate melanoma transection with initial biopsy does not impact patient survival; however, tumor transaction can lead to misdiagnosis and inaccurate staging. Objective: This study assessed the rate of melanoma transaction with various biopsy techniques and the impact of tumor transaction on patient survival. Methods: We conducted a retrospective review of all melanoma cases at our institution between 2000 and 2008. Of the 490 melanoma cases identified, 479 met inclusion criteria for the study. The transaction rates of biopsy techniques were determined. Cases of transected ...

Skin Health

Search This Blog